ATLANTA, Jun 29, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc., (Nasdaq:ALIM), ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Iluvien(R), (flucocinolone acetonide intravitreal insert), its investigational, sustained drug delivery system releasing sub-microgram levels of fluocinolone acetonide for the treatment of diabetic macular edema (DME). In the submission, Alimera requested priority review, which, if granted, could result in an action letter from the FDA in the fourth quarter of 2010.
"This is a significant milestone for all of us at Alimera, and represents a major advance toward a rapid and sustained visual acuity benefit for DME sufferers," said Dan Myers, president and CEO of Alimera, adding, "We believe that Iluvien(R), if approved, will provide a needed alternative to the multiple injections of corticosteroids and anti-VEGF therapies used off-label for extended efficacy in DME. We believe this would be the first ophthalmic drug therapy to be approved for DME and the only DME treatment that works in terms of years, not months."
More
Shares Now Trading on NASDAQ Global Market Under Symbol "ALIM"
ATLANTA, Apr 23, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc. (Nasdaq:ALIM), ("Alimera") today announced that it priced its initial public offering of 6,550,000 shares of common stock at a price to the public of $11.00 per share on Wednesday, April 21, 2010.
In addition, Alimera has granted the underwriters a 30-day option to purchase up to an additional 982,500 shares to cover over-allotments, if any. The gross proceeds of the offering, before expenses, from the sale of shares, are expected to be $72.05 million, assuming the 30-day over-allotment option is not exercised. The closing of the offering is expected to take place on April 27, 2010.
Credit Suisse Securities (USA) LLC and Citigroup Global Markets Inc. are acting as joint book-running managers for the offering.
Shares of Alimera common stock began trading on the NASDAQ Global Market under the symbol "ALIM" on Thursday, April 22, 2010.
This registration statement relating to the initial public offering of shares of common stock of Alimera has been declared effective by the U.S. Securities and Exchange Commission.
More